Development of allosteric modulators of GPCRs for treatment of CNS disorders

Neurobiology of Disease

Volumn 61, Issue , 2014, Pages 55-71

  Nickols, Hilary Highfield ^a   Conn, Jeffrey P ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric modulator; CNS; Drug discovery; GPCR; Metabotropic glutamate receptor; Muscarinic acetylcholine receptor

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ADX 48621; ADX 71149; ADX 71743; ADX 88178; AF 21934; AF 267; AF 32615; AMANTADINE; BRUCINE; DCPG; DIPRAGLURANT; DIZOCILPINE; EGLUMETAD; FENOBAM; G PROTEIN COUPLED RECEPTOR; GRN 529; JNJ 16259685; LEVODOPA; LSP1 2111; MAVOGLURANT; METABOTROPIC RECEPTOR ANTAGONIST; MMPIP; MUSCARINIC AGENT; RG 7090; SCH 412384; UNCLASSIFIED DRUG; VU 0029767; VU 0090157; VU 0364770; VU 0424465; VU 463841; XANOMALINE;

ADDICTION; ALLOSTERISM; ALZHEIMER DISEASE; ANXIETY DISORDER; AUTISM; CHRONIC PAIN; COCAINE DEPENDENCE; COGNITIVE DEFECT; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MIGRAINE; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

1-(1′-(2-METHYLBENZYL)-1,4′-BIPIPERIDIN-4-YL)-1H-BENZO[D]IMIDAZOL-2(3H)-ONE; 2-CHLORO-4-((2,5-DIMETHYL-1-(4-(TRIFLUOROMETHOXY)PHENYL)-1HIMIDAZOL-4-YL)ETHYNYL)PYRIDINE; 3-CYCLOHEXYL-5-FLUORO-6-METHYL-7-(2-MORPHOLIN-4-YLETHOXY)-4H-CHROMEN-4-ONE; 4-[1-(2-FLUOROPYRIDIN-3-YL)-5-METHYL-1H-1,2,3-TRIAZOL-4-YL]-N-ISOPROPYL-N-METHYL-3,6-DIHYDROPYRIDINE-1(2H)-CARBOXAMIDE; 6-(4-METHOXYPHENYL)-5-METHYL-3-(4-PYRIDINYL)-ISOXAZOLO[4,5-C]PYRIDIN-4(5H)-ONE; N-[4-CHLORO-2[(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)METHYL]PHENYL]-2-HYDROBENZAMIDE; (+)-6-(2,4-DIMETHYLPHENYL)-2-ETHYL-6,7-DIHYDROBENZO[D]OXAZOL-4(5H)-ONE; (1-(4-CYANO-4-(PYRIDINE-2-YL)PIPERIDINE-1-YL)METHYL-4-OXO-4H-QUINOLIZINE-3-CARBOXYLIC ACID); (1S,2S)-N(1)-(3,4-DICHLOROPHENYL)CYCLOHEXANE-1,2-DICARBOXAMIDE; (1S,3R,4S)-1-AMINOCYCLO-PENTANE-1,3,4-TRICARBOXYLIC ACID; (3,4-DIHYDRO-2H-PYRANO[2,3]B QUINOLIN-7-YL)(CIS-4-METHOXYCYCLOHEXYL) METHANONE; (3AS,5S,7AR)-METHYL 5-HYDROXY-5-(M-TOLYLETHYNYL)OCTAHYDRO-1H-INDOLE-1-CARBOXYLATE; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-[3-(4-BUTYL-1-PIPERIDINYL)PROPYL]-3,4-DIHYDRO-2(1H)-QUINOLINONE; 2-(2-(3-METHOXYPHENYL)ETHYNYL)-5-METHYLPYRIDINE; 2-METHYL-6-(2-PHENYLETHENYL)PYRIDINE; 2-METHYL-6-(PHENYLETHYNYL)-PYRIDINE; 3-CYANO-N-(1,3-DIPHENYL-1H-PYRAZOL-5-YL)BENZAMIDE; 3[(2-METHYL-1,3-THIAZOL-4-YL)ETHYLNYL]PYRIDINE; 4-((E)-STYRYL)-PYRIMIDIN-2-YLAMINE; 4-N-BUTYL-1-[4-(2-METHYLPHENYL)-4-OXO-1-BUTYL]-PIPERIDINE; 5-METHYL-6-(PHENYLETHYNYL)-PYRIDINE; 5MPEP; 6-HYDROXYDOPAMINE; 6-METHYL-2-(PHENYLAZO)-3-PYRIDINOL; 6-OHDA; 77-LH-28-1; 7TMR; AC-42; ACETYLCHOLINESTERASE; ACHE; ACPT-1; AD; ADX71743; AFQ056; ALLOSTERIC MODULATOR; ALZHEIMER'S DISEASE; AMYLOID PRECURSOR PROTEIN; APP; BENZYLQUINOLONE CARBOXYLIC ACID; BINA; BQCA; CDPPB; CENTRAL NERVOUS SYSTEM; CFMMC; CNS; CPPHA; CTEP; DA; DFB; DHPG; DIHYDROXYPHENYLGLYCINE; DOPAMINE; DRUG DISCOVERY; ERK1/2; EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2; FMRP; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; FTIDC; FXS; GABA; GPCR; JNJ16259685; L-(+)-2-AMINO-4-PHOSPHONOBUTYRIC ACID; L-3,4-DIHYDROXYPHENYLALANINE; L-AP4; L-DOPA; LU AF21934; LU AF32615; M-5MPEP; METABOTROPIC GLUTAMATE RECEPTOR; MGLU; MMPIP; MPEP; MPTP; MTEP; MUSCARINIC ACETYLCHOLINE RECEPTOR; N-METHYL-D-ASPARTATE; N-PHENYL-7-(HYDROXYLIMINO)CYCLOPROPA[B]CHROMEN-1A-CARBOXAMIDE; NAM; NEGATIVE ALLOSTERIC MODULATOR; NMDA; PAM; PARKINSON'S DISEASE; PARKINSON'S DISEASE LEVODOPA-INDUCED DYSKINESIA; PCP; PD; PD-LID; PET; PHCCC; PHENCYCLIDINE; POSITIVE ALLOSTERIC MODULATOR; POSITRON EMISSION TOMOGRAPHY; POTASSIUM 30-([(2-CYCLOPENTYL-6-7-DIMETHYL-1-OXO-2,3-DIHYDRO-1H-INDEN-5YL)OXY]METHYL)BIPHENYL L-4-CARBOXYLATE; PQCA; SAM; SEVEN TRANSMEMBRANE RECEPTOR; SIB-1757; SIB-1893; SILENT ALLOSTERIC MODULATOR; TBPB; [(3-FLUOROPHENYL)METHYLENE]HYDRAZONE-3-FLUOROBENZALDEHYDE; Γ-AMINOBUTYRIC ACID;

ALLOSTERIC REGULATION; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84888040704     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.013     Document Type: Review

References (321)

1. Abe T., et al. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem. 1992, 267:13361-13368.
2. Achat-Mendes C., et al. Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. J. Pharmacol. Exp. Ther. 2012, 343:214-224.
3. Adams D.H., et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013, 13:143.
4. Adewale A.S., et al. Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. J. Pharmacol. Exp. Ther. 2006, 318:922-931.
5. Adler C.M., et al. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry 1998, 43:811-816.
6. Allen J.A., Roth B.L. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2011, 51:117-144.
7. Amato R.J., Felts A.S., et al. Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu: Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of Cocaine Addiction. ACS Chem. Neurosci. 2013, 4:1217-1228.
8. Anagnostaras S.G., et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
9. Annoura H F.A., Uesugi M., Tatsuoka T., Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(ydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg. Med. Chem. Lett. 1996, 6(7):763-766.
10. Auerbach B.D., et al. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68.
11. Awad H., et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20:7871-7879.
12. Ayala J.E., Chen Y., et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34(9):2057-2071.
13. Bartus R.T., et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
14. Battaglia G., et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 2006, 26:7222-7229.
15. Bear M.F., et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
16. Belozertseva I.V., et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 2007, 17:172-179.
17. Bennett C.E., et al. Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg. Med. Chem. Lett. 2012, 22:1575-1578.
18. Benneyworth M.A., Xiang Z., et al. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 2007, 72(2):477-484.
19. Bennouar K.E., et al. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 2013, 66:158-169.
20. Betz A.J., McLaughlin P.J., et al. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl) 2007, 194(3):347-359.
21. Bhagwanth S., et al. Transformation of Pro-Leu-Gly-NH(2) peptidomimetic positive allosteric modulators of the dopamine D(2) receptor into negative modulators. ACS Chem. Neurosci. 2012, 3:274-284.
22. Bhakar A.L., et al. The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 2012, 35:417-443.
23. Bird M.K., Lawrence A.J. Group I metabotropic glutamate receptors: involvement in drug-seeking and drug-induced plasticity. Curr. Mol. Pharmacol. 2009, 2:83-94.
24. Blandini F., et al. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 2000, 62:63-88.
25. Bodick N.C., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997, 54:465-473.
26. Bodick N.C., et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1997, 11(Suppl. 4):S16-S22.
27. Bogenpohl J., et al. Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex. Neuropharmacology 2013, 66:242-252.
28. Bogoyevitch M.A., Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 2007, 12:622-633.
29. Bourke D., Druckenbrod R.W. Possible association between donepezil and worsening Parkinson's disease. Ann. Pharmacother. 1998, 32:610-611.
30. Bradley S.R., et al. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J. Comp. Neurol. 1999, 407:33-46.
31. Bradley S.R., et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J. Neurosci. 2000, 20:3085-3094.
32. Brady A.E., Jones C.K., et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 2008, 327(3):941-953.
33. Bridges T.M., Marlo J.E., et al. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J. Med. Chem. 2009, 52(11):3445-3448.
34. Bridges T.M., et al. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM. Bioorg. Med. Chem. Lett. 2010, 20:1972-1975.
35. Bridges T.M., LeBois E.P., et al. The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect. 2010, 23(4):229-240.
36. Bridges T.M., Lewis L.M., et al. Discovery and development of the a highly selective M1 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD) 2010.
37. Bridges T.M., Niswender C.M., et al. Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM) Series with Greatly Improved Human Receptor Activity. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD) 2010.
38. Bridges T.M., Reid P.R., et al. Discovery and development of a second highly selective M1 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD) 2010.
39. Bridges T.M., et al. Biotransformation of a novel positive allosteric modulator of mGlu5 contributes to seizures in rats involving a receptor agonism-dependent mechanism. Drug Metab. Dispos. 2013, 41(9):1703-1714.
40. Brody S.A., et al. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 2004, 172:187-195.
41. Brody S.A., et al. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol. Psychiatry 2004, 9:35-41.
42. Bruno V., et al. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci. 2000, 20:6413-6420.
43. Burford N.T., et al. Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10830-10835.
44. Caccamo A., et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
45. Campbell U.C., et al. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 2004, 175:310-318.
46. Campo B., et al. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J. Neurogenet. 2011, 25:152-166.
47. Cartmell J., et al. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 1999, 291:161-170.
48. Celanire S., Campo B. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. Expert Opin. Drug Discov. 2012, 7(3):261-280.
49. Chaki S., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
50. Chaki S., et al. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013, 66:40-52.
51. Chan W.Y., McKinzie D.L., et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(31):10978-10983.
52. Chaudhuri K.R., et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
53. Chiamulera C., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 2001, 4:873-874.
54. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54:323-374.
55. Clifton N.E., et al. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology 2013, 225:579-594.
56. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
57. Conn P.J., et al. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 2005, 6:787-798.
58. Conn P.J., et al. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv. 2008, 8:99-107.
59. Conn P.J., et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8:41-54.
60. Conn P.J., et al. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 2009, 30:148-155.
61. Conn P.J., et al. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30:25-31.
62. Conn P.J., Kuduk S.D., Doller D. Drug Design Strategies for GPCR Allosteric Modulators. Annual Reports in Medicinal Chemistry 2012, 441-457. Academic Press, Burlington. I.M.C. Desai (Ed.).
63. Cosford N.D., Tehrani L., et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46(2):204-206.
64. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
65. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004, 174:32-38.
66. Crook J.M., et al. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 2000, 48:381-388.
67. Darrah J.M., et al. Interaction of N-methyl-d-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol. 2008, 19:225-234.
68. Davey A.E., et al. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 2012, 153:1232-1241.
69. Dawson L., et al. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br. J. Pharmacol. 2000, 129:541-546.
70. De Luca V., et al. Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 2004, 50:124-127.
71. Dean B., et al. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2002, 7:1083-1091.
72. Dekundy A., et al. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 2006, 69:318-326.
73. Dencker D., et al. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. J. Neurosci. 2011, 31:5905-5908.
74. Deng C., Huang X.F. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J. Neurosci. Res. 2005, 81:883-890.
75. Dickerson J.W., Conn P.J. Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. Neurodegener. Dis. Manag. 2012, 2:221-232.
76. Digby G.J., Noetzel M.J., et al. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J. Neurosci. 2012, 32(25):8532-8544.
77. Digby G.J., Utley T.J., et al. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. ACS Chem. Neurosci. 2012, 3(12):1025-1036.
78. Doherty A.J., et al. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br. J. Pharmacol. 2000, 131:239-244.
79. Dolen G., et al. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
80. Doria J., et al. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. Br. J. Pharmacol. 2013, 169:909-921.
81. East S.P., Bamford S., et al. An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg. Med. Chem. Lett. 2010, 20(16):4901-4905.
82. Emmitte K.A. mGlu5 negative allosteric modulators: a patent review (2010-2012). Expert Opin. Ther. Pat. 2013, 23:393-408.
83. Engers D.W., et al. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J. Med. Chem. 2009, 52:4115-4118.
84. Engers D.W., et al. Discovery of a novel metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulator (PAM) extended probe: characterization of ML292, a potent and selective mGlu4 PAM which produces efficacy alone or in combination with L-DOPA in preclinical rodent models of Parkinson's disease. Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD) 2010.
85. Fabbrini G., et al. Levodopa-induced dyskinesias. Mov. Disord. 2007, 22:1379-1389. (quiz 1523).
86. Fallarino F., et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat. Med. 2010, 16:897-902.
87. Fang Y., et al. G protein-coupled receptor microarrays for drug discovery. Drug Discov. Today 2003, 8:755-761.
88. Feinberg I., et al. The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol. Biochem. Behav. 2002, 73:467-474.
89. Feldman H. Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?. Int. Psychogeriatr. 2002, 14(Suppl. 1):3-5.
90. Fell M.J., et al. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
91. Fell M.J., et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methy l-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J. Pharmacol. Exp. Ther. 2011, 336:165-177.
92. Field J.R., et al. Targeting glutamate synapses in schizophrenia. Trends Mol. Med. 2011, 17:689-698.
93. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease-the pivotal role of brain M1 receptors. Neurodegener. Dis. 2008, 5:237-240.
94. Friedmann C.T.H., Davis L.J., Ciccone P.E., Rubin R.T. Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr. Ther. Res. 1980, 27:144-151.
95. Galici R., Jones C.K., et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 318(1):173-185.
96. Garcia-Perez J., et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J. Biol. Chem. 2011, 286:33409-33421.
97. Gasparini F., Lingenhohl K., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38(10):1493-1503.
98. Gastambide F., Gilmour G., et al. The mGlu(5) positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 2013, 64:240-247.
99. Gilmour G., Broad L.M., et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu(5) receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 2013, 64:224-239.
100. Goeldner C., Ballard T.M., et al. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 2013, 64:337-346.
101. Goudet C., et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2008, 137:112-124.
102. Greenamyre J.T., O'Brien C.F. N-methyl-d-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 1991, 48:977-981.
103. Gregory K.J., et al. Probing the metabotropic glutamate receptor 5 (mGlu(5)) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Mol. Pharmacol. 2013, 83:991-1006.
104. Grossberg G.T. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int. Psychogeriatr. 2002, 14(Suppl. 1):27-49.
105. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 1995, 18:237-249.
106. Hanyu H., et al. Effect of age on regional cerebral blood flow patterns in Alzheimer's disease patients. J. Neurol. Sci. 2003, 209:25-30.
107. Hashimoto K., Malchow B., et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(5):367-377.
108. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 2006, 16:710-715.
109. Hasselmo M.E., Giocomo L.M. Cholinergic modulation of cortical function. J. Mol. Neurosci. 2006, 30:133-135.
110. Heinrich J.N., et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharmacol. 2009, 605:53-56.
111. Hemstapat K., de Paulis T., et al. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 2006, 70(2):616-626.
112. Hemstapat K., Da Costa H., et al. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 2007, 322(1):254-264.
113. Henry S.A., et al. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43:1199-1209.
114. Herman E.J., et al. Metabotropic glutamate receptors for new treatments in schizophrenia. Handb. Exp. Pharmacol. 2012, 297-365.
115. Hikichi H., Murai T., et al. Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents. Eur. J. Pharmacol. 2010, 639(1-3):106-114.
116. Hirsch E.C., et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 2000, 23:S78-S85.
117. Hogg R.C., et al. Allosteric modulation of ligand-gated ion channels. Biochem. Pharmacol. 2005, 70:1267-1276.
118. Hopkins C.R. Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?. ACS Chem. Neurosci. 2013, 4:211-213.
119. Hopkins C.R., et al. mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. Future Med. Chem. 2009, 1:501-513.
120. Huang Z., et al. ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res. 2011, 39:D663-D669.
121. Hughes Z.A., Neal S.J., et al. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2013, 66:202-214.
122. Ince E., et al. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 1997, 27:357-366.
123. Itil T.M., Seaman B.A., Huque M., Mukhopadhyay S., Blasucci D., Tat K., Ciccone P.E. The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr. Ther. Res. 1978, 708-724.
124. Jacquemont S., Curie A., et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 2011, 3(64):64ra1.
125. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006, 5:864-872.
126. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
127. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 1987, 9:12-35.
128. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
129. Jimenez H.N., et al. 4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators. Bioorg. Med. Chem. Lett. 2012, 22:3235-3239.
130. Johnson M.P., Baez M., et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 2003, 46(15):3189-3192.
131. Johnson K.A., et al. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8:475-491.
132. Johnson K.A., et al. Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata. Neurosci. Lett. 2011, 504:102-106.
133. Johnson K.A., et al. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology 2013, 66:187-195.
134. Jones C.K., et al. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 2005, 49(Suppl. 1):206-218.
135. Jones C.K., Brady A.E., et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008, 28(41):10422-10433.
136. Jones C.K., et al. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J. Med. Chem. 2011, 54:7639-7647.
137. Jones C.K., Bubser M., et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2012, 340(2):404-421.
138. Jones C.K., et al. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37:16-42.
139. Kalinichev M., Rouillier M., et al. ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 2013, 344(3):624-636.
140. Katritch V., et al. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53:531-556.
141. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 2005, 4:919-927.
142. Kenakin T. G protein coupled receptors as allosteric proteins and the role of allosteric modulators. J. Recept. Signal Transduct. Res. 2010, 30:313-321.
143. Kenakin T., Miller L.J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 2010, 62:265-304.
144. Kenny P.J., et al. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology 2005, 179:247-254.
145. Keywood C., et al. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009, 58:1192-1199.
146. Kim D.H., et al. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009, 6:78-85.
147. Kinney G.G., et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2003, 306:116-123.
148. Kinon B.J., et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 2011, 31:349-355.
149. Klein M.T., et al. Approaches for probing allosteric interactions at 7 transmembrane spanning receptors. Prog. Mol. Biol. Transl. Sci. 2013, 115:1-59.
150. Knoflach F., Mutel V., et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(23):13402-13407.
151. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
152. Konieczny J., et al. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 2007, 145:611-620.
153. Krueger D.D., Bear M.F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 2011, 62:411-429.
154. Krystal J.H., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
155. Kulisevsky J., Poyurovsky M. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. Eur. Neurol. 2012, 67:4-11.
156. Kumar N., et al. Metabotropic glutamate receptors (mGluRs) regulate noxious stimulus-induced glutamate release in the spinal cord dorsal horn of rats with neuropathic and inflammatory pain. J. Neurochem. 2010, 114:281-290.
157. Kumaresan V., et al. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav. Brain Res. 2009, 202:238-244.
158. Lahti A.C., et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
159. Langmead C.J., Austin N.E., et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 2008, 154(5):1104-1115.
160. Langmead C.J., et al. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 2008, 117:232-243.
161. Lavieri R.R., et al. Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J. Med. Chem. 2010, 53:6706-6719.
162. Lavreysen H., Pereira S.N., et al. Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology 2004, 46(5):609-619.
163. Lazareno S., et al. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol. Pharmacol. 1998, 53:573-589.
164. Lazareno S., Birdsall B., et al. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 1999, 64(6-7):519-526.
165. Lazareno S., Dolezal V., et al. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004, 65(1):257-266.
166. Le Poul E., et al. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2012, 343:167-177.
167. Le U., et al. Discovery of a selective M(4) positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorg. Med. Chem. Lett. 2013, 23:346-350.
168. Leach K., et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2010, 35:855-869.
169. Lebois E.P., Bridges T.M., et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem. Neurosci. 2010, 1(2):104-121.
170. Lebon G., et al. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 2009, 75:331-341.
171. Lecourtier L., et al. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol. Psychiatry 2007, 62:739-746.
172. Lee C.M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol. Sci. 2006, 27:310-316.
173. Lee B., et al. Attenuation of behavioral effects of cocaine by the Metabotropic Glutamate Receptor 5 Antagonist 2-Methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J. Pharmacol. Exp. Ther. 2005, 312:1232-1240.
174. Levandis G., et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol. Dis. 2008, 29:161-168.
175. Levey A.I., et al. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991, 11:3218-3226.
176. Levey A.I., et al. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J. Neurosci. 1995, 15:4077-4092.
177. Lewis J.A., et al. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr. Opin. Chem. Biol. 2008, 12:269-280.
178. Li X., et al. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 319:254-259.
179. Liao D.L., et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003, 48:72-76.
180. Liechti M.E., Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur. J. Pharmacol. 2007, 554:164-174.
181. Lindemann L., Jaeschke G., et al. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J. Pharmacol. Exp. Ther. 2011, 339(2):474-486.
182. Lindsley C.W., et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:761-764.
183. Lindsley C.W., et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 2006, 6:771-785.
184. Liu F., Grauer S., et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1- yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther. 2008, 327(3):827-839.
185. Lockhart I.A., et al. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement. Geriatr. Cogn. Disord. 2009, 28:389-403.
186. Lopez S., et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci. 2007, 27:6701-6711.
187. Lorrain D.S., et al. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 2003, 28:1622-1632.
188. Ma L., et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15950-15955.
189. Mabire D., et al. Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J. Med. Chem. 2005, 48:2134-2153.
190. MacInnes N., et al. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br. J. Pharmacol. 2004, 141:15-22.
191. Maj M., Bruno V., et al. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 2003, 45(7):895-906.
192. Malhotra A.K., et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14:301-307.
193. Malhotra A.K., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
194. Marek G.J. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition. Eur. J. Pharmacol. 2010, 639:81-90.
195. Marik J., Sanabria Bohorquez S., Williams S.-P., van Bruggen N. New imaging paradigms in drug development: the PET imaging approach. Drug Discovery Today: Technologies 2011, 2011. Elsevier. N. W. B. Beckmann, K. Lam, H. Timmerman (Eds.).
196. Marino M.J., Williams D.L., et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(23):13668-13673.
197. Marlo J.E., et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. 2009, 75:577-588.
198. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977, 1:345-349.
199. Martella G., et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009, 132:2336-2349.
200. Martin L.J., et al. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 1992, 9:259-270.
201. Martino G., et al. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action. Pain 2011, 152:2852-2860.
202. Mathiesen J.M., et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 2005, 68:393-402.
203. Matsui T., Kita H. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience 2003, 122:727-737.
204. May L.T., Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 2003, 3:551-556.
205. Meissner W.G., et al. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
206. Mela F., et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 2007, 101:483-497.
207. Melancon B.J., et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem. 2012, 55:1445-1464.
208. Melancon B.J., et al. Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Bioorg. Med. Chem. Lett. 2013, 23:412-416.
209. Michalon A., et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012, 74:49-56.
210. Miyakawa T., et al. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 2001, 21:5239-5250.
211. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004, 174:39-44.
212. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
213. Mohler H., et al. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 2002, 300:2-8.
214. Montana M.C., et al. The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J. Pharmacol. Exp. Ther. 2009, 330:834-843.
215. Morin N., et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
216. Morin N., et al. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 2013, 66:355-364.
217. Morin N., et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology 2013, 73C:216-231.
218. Morishima Y., et al. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4170-4175.
219. Murray T.K., et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav. 2002, 73:455-466.
220. Nawaratne V., et al. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 2010, 285:19012-19021.
221. Nemeth E.F., et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 2004, 308:627-635.
222. Newcomer J.W., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
223. Nicoletti F., et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011, 60:1017-1041.
224. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
225. Niswender C.M., Johnson K.A., et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 2008, 74(5):1345-1358.
226. Niswender C.M., Johnson K.A., et al. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol. Pharmacol. 2010, 77(3):459-468.
227. Noetzel M.J., et al. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol. 2013, 83:835-847.
228. Osterholm R.K., Camoriano J.K. Transdermal scopolamine psychosis. JAMA 1982, 247:3081.
229. Ott B.R., Lannon M.C. Exacerbation of parkinsonism by tacrine. Clin. Neuropharmacol. 1992, 15:322-325.
230. Ouattara B., et al. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J. Neurochem. 2010, 113:715-724.
231. Palucha A., et al. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav. 2005, 81:901-906.
232. Palucha-Poniewiera A., et al. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) 2010, 212:523-535.
233. Parmentier-Batteur S., et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - development challenges for a promising novel antipsychotic target. Neuropharmacology 2013, (in press).
234. Parwani A., et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 2005, 183:265-274.
235. Patil S.T., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
236. Pecknold J.C., et al. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 1982, 2:129-133.
237. Pellegrino D., et al. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J. Nucl. Med. 2007, 48:1147-1153.
238. Pilc A., et al. Glutamate-based antidepressants: preclinical psychopharmacology. Biol. Psychiatry 2013, 73:1125-1132.
239. Pisani A., et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106:579-587.
240. Pisani A., et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
241. Platt D.M., et al. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology 2008, 200:167-176.
242. Porter R.H., Jaeschke G., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 2005, 315(2):711-721.
243. Poslusney M.S., et al. Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Bioorg. Med. Chem. Lett. 2013, 23:1860-1864.
244. Prashanth L.K., et al. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int. Rev. Neurobiol. 2011, 98:31-54.
245. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S3-S7.
246. Raffa R.B. The M5 muscarinic receptor as possible target for treatment of drug abuse. J. Clin. Pharm. Ther. 2009, 34:623-629.
247. Reid P.R., et al. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg. Med. Chem. Lett. 2011, 21:2697-2701.
248. Robichaud A.J., et al. Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. ACS Chem. Neurosci. 2011, 2:433-449.
249. Robinson L., et al. Involvement of the cholinergic system in conditioning and perceptual memory. Behav. Brain Res. 2011, 221:443-465.
250. Rodriguez A.L., Nong Y., et al. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 2005, 68(6):1793-1802.
251. Rodriguez A.L., Grier M.D., et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 2010, 78(6):1105-1123.
252. Rook J.M., et al. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol. Psychiatry 2013, 73(6):501-509.
253. Rosenbrock H., et al. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 2010, 639:40-46.
254. Rowland L.M. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat. Space Environ. Med. 2005, 76:C52-C58.
255. Rylander D., et al. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
256. Rylander D., et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
257. Sachpatzidis A., et al. Identification of allosteric peptide agonists of CXCR4. J. Biol. Chem. 2003, 278:896-907.
258. Salamone J.D., et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci. 2001, 68:2579-2584.
259. Samadi P., et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 2008, 29:1040-1051.
260. Sanacora G., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
261. Santoro M.R., et al. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 2012, 7:219-245.
262. Schkeryantz J.M., et al. Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain. J. Med. Chem. 2007, 50:2563-2568.
263. Schlumberger C., et al. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur. J. Pharmacol. 2009, 623:73-83.
264. Schlumberger C., et al. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol. Biochem. Behav. 2010, 95:23-30.
265. Schoepp D.D., Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:215-225.
266. Schoepp D.D., et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
267. Scott S.A., et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem. Biol. 2009, 5:108-117.
268. Sheffler D.J., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology 2008, 55:419-427.
269. Sheffler D.J., Wenthur C.J., et al. Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg. Med. Chem. Lett. 2012, 22(12):3921-3925.
270. Shekhar A., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
271. Shigemoto R., et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 1993, 163:53-57.
272. Shirey J.K., et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008, 4:42-50.
273. Shirey J.K., Brady A.E., et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 2009, 29(45):14271-14286.
274. Sibille P., et al. Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J. Med. Chem. 2007, 50:3585-3595.
275. Silverman J.L., et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med. 2012, 4. (131ra51).
276. Slawinska A., Wieronska J.M., et al. The antipsychotic-like effects of mGlu4 receptor positive allosteric modulators in rodents. Br. J. Pharmacol. 2013, 227(4):711-725.
277. Slawinska A., Wieronska J.M., et al. Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu(4) receptor. Neuropharmacology 2013, 66:225-235.
278. Smith R., et al. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet. 2006, 15:3119-3131.
279. Sofuoglu M., Mooney M. Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs 2009, 23:939-952.
280. Spalding T.A., Trotter C., et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 2002, 61(6):1297-1302.
281. Stefani M.R., Moghaddam B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 2010, 639:26-32.
282. Sur C., Mallorga P.J., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(23):13674-13679.
283. Swanson C.J., et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 2005, 4:131-144.
284. Tabolacci E., et al. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med. Genet. 2012, 13:13.
285. Tandon R., et al. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr. Res. 1991, 4:23-30.
286. Taylor D.L., et al. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J. Neurosci. 2003, 23:2150-2160.
287. Thomas N.K., Wright R.A., et al. (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 2001, 40(3):311-318.
288. Thomas A.M., Bui N., et al. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology 2012, 219(1):47-58.
289. Thomsen M., et al. Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation. J. Pharmacol. Exp. Ther. 2010, 332:959-969.
290. Thomsen M., et al. Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice. Psychopharmacology (Berl) 2012, 220:673-685.
291. Tsai P., Sahin M. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. Curr. Opin. Neurol. 2011, 24:106-113.
292. Ugolini A., Large C.H., et al. AMN082, an allosteric mGluR7 agonist that inhibits afferent glutamatergic transmission in rat basolateral amygdala. Neuropharmacology 2008, 55(4):532-536.
293. Uslaner J.M., Eddins D., et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology (Berl) 2013, 225(1):21-30.
294. Utley T., et al. Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator. Bioorg. Med. Chem. Lett. 2011, 21:6955-6959.
295. Valenti O., et al. Modulation of excitatory transmission onto midbrain dopaminergic neurons of the rat by activation of group III metabotropic glutamate receptors. Ann. N. Y. Acad. Sci. 2003, 1003:479-480.
296. Valenti O., et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci. 2003, 23:7218-7226.
297. Valenti O., et al. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther. 2005, 313:1296-1304.
298. van Bon B.W., et al. The phenotype of recurrent 10q22q23 deletions and duplications. Eur. J. Hum. Genet. 2011, 19:400-408.
299. Vanover K.E., et al. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav. Neurosci. 2008, 122:570-575.
300. Vardigan J.D., et al. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?. Pharmacol. Biochem. Behav. 2010, 95:223-229.
301. Varty G.B., et al. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 2008, 200:393-401.
302. Vilaro M.T., et al. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett. 1990, 114:154-159.
303. Wang H., et al. Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. Neuropsychopharmacology 2004, 29:2126-2139.
304. Wei H., et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10782-10787.
305. Weiner D.M., et al. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7050-7054.
306. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 1996, 6:751-758.
307. Wichmann J., Bleicher K., et al. Alkyl diphenylacetyl, 9H-xanthene- and 9H-thioxanthene-carbonyl carbamates as positive allosteric modulators of mGlu1 receptors. Farmaco 2002, 57(12):989-992.
308. Wieronska J.M., et al. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl) 2012, 220:481-494.
309. Wieronska J.M., et al. The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT(1)A signalling. Psychopharmacology (Berl) 2013, 227:711-725.
310. Williams M.J., Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2008, 33:1779-1797.
311. Wood M.R., et al. "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 2011, 50:2403-2410.
312. Woolley M.L., et al. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol. 2009, 603:147-149.
313. Wootten D., et al. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 2013, 12:630-644.
314. Yamada M., et al. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14096-14101.
315. Yang F.V., et al. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M(1) positive allosteric modulators. Bioorg. Med. Chem. Lett. 2010, 20:531-536.
316. Yu F., et al. Metabotropic glutamate receptor I (mGluR1) antagonism impairs cocaine-induced conditioned place preference via inhibition of protein synthesis. Neuropsychopharmacology 2013, 38:1308-1321.
317. Zarate C.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
318. Zavitsanou K., et al. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29:619-625.
319. Zerbib F., et al. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 2010, 22(859-65):e231.
320. Zhang C., Marek G.J. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation. J. Pharmacol. Exp. Ther. 2007, 320(1):437-447.
321. Zhang Y., et al. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 2005, 315:1212-1219.